Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater

被引：0
|
作者：
Tambo, Yuichi [1 ]
Sone, Takashi [1 ]
Shibata, Kazuhiko [2 ]
Nishi, Kouichi [3 ]
Shirasaki, Hiroki [4 ]
Yoneda, Taro [5 ]
Araya, Tomoyuki [6 ]
Kase, Kazumasa [7 ]
Nishikawa, Shingo [1 ]
Kimura, Hideharu [1 ]
Kasahara, Kazuo [1 ]
机构：
[1] Kanazawa Univ Hosp, Resp Med, Kanazawa, Ishikawa, Japan
[2] Kouseiren Takaoka Hosp, Dept Med Oncol, Takaoka, Toyama, Japan
[3] Ishikawa Prefectural Cent Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan
[4] Fukui Ken Saiseikai Hosp, Dept Resp Med, Fukui, Japan
[5] Komatsu Municipal Hosp, Dept Resp Med, Komatsu, Japan
[6] Natl Hosp Org Kanazawa Med Ctr, Dept Resp Med, Kanazawa, Ishikawa, Japan
[7] Keiju Med Ctr, Dept Internal Med, Nanao, Japan
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.05.626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO25-3
引用
收藏
页码：S313 / S313
页数：1
相关论文
共 50 条
  • [21] Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC
    Takeyasu, Yuki
    Yoshida, Tatsuya
    Shibaki, Ryota
    Matsumoto, Yuji
    Goto, Yasushi
    Kanda, Shintaro
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Motoi, Noriko
    Ohe, Yuichiro
    CLINICAL LUNG CANCER, 2021, 22 (02) : 127 - +
  • [22] Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
    Frost, N.
    Kollmeier, J.
    Pultermann, D.
    Tessmer, A.
    Schmittel, A.
    Schmidt, B.
    Grah, C.
    de Wit, M.
    Misch, D.
    Blum, T.
    Suttorp, N.
    Grohe, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: A multiomics approach.
    Garassino, Marina Chiara
    Proto, Claudia
    Dolezal, James M.
    Prelaj, Arsela
    Agnelli, Luca
    Triulzi, Tiziana
    Fabbri, Alessandra
    Ferrara, Roberto
    Sgambelluri, Francesco
    Torelli, Tommaso
    Brich, Silvia
    Manglaviti, Sara
    Anichini, Andrea
    Mortarini, Roberta
    Trinchieri, Giorgio
    Pruneri, Giancarlo
    De Braud, Filippo G.
    Torri, Valter
    Ganzinelli, Monica
    Lo Russo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 &lt;50%: a multiomics analysis
    Lo Russo, Giuseppe
    Prelaj, Arsela
    Dolezal, James
    Beninato, Teresa
    Agnelli, Luca
    Triulzi, Tiziana
    Fabbri, Alessandra
    Lorenzini, Daniele
    Ferrara, Roberto
    Brambilla, Marta
    Occhipinti, Mario
    Mazzeo, Laura
    Provenzano, Leonardo
    Spagnoletti, Andrea
    Viscardi, Giuseppe
    Sgambelluri, Francesco
    Brich, Silvia
    Miskovic, Vanja
    Pedrocchi, Alessandra Laura Giulia
    Trovo', Francesco
    Manglaviti, Sara
    Giani, Claudia
    Ambrosini, Paolo
    Leporati, Rita
    Franza, Andrea
    Mcculloch, John
    Torelli, Tommaso
    Anichini, Andrea
    Mortarini, Roberta
    Trinchieri, Giorgio
    Pruneri, Giancarlo
    Torri, Valter
    De Braud, Filippo
    Proto, Claudia
    Ganzinelli, Monica
    Garassino, Marina Chiara
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
  • [25] Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
    Ou Yamaguchi
    Kyoichi Kaira
    Kosuke Hashimoto
    Atsuto Mouri
    Ayako Shiono
    Yu Miura
    Yoshitake Murayama
    Kunihiko Kobayashi
    Hiroshi Kagamu
    Ichiei Kuji
    Scientific Reports, 10
  • [26] Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50%
    Yamaguchi, Ou
    Kaira, Kyoichi
    Hashimoto, Kosuke
    Mouri, Atsuto
    Shiono, Ayako
    Miura, Yu
    Murayama, Yoshitake
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    Kuji, Ichiei
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [27] Long-term real- world outcomes of first-line (1L) pembrolizumab (pembro) monotherapy in PD-L1 ≥50% metastatic NSCLC.
    Velcheti, Vamsidhar
    Hu, Xiaohan
    Piperdi, Bilal
    Yang, Lingfeng
    Burke, Thomas A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
    Sezer, A.
    Gogishvili, M.
    Bentsion, D.
    Kilickap, S.
    Lowczak, A.
    Gumus, M.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Lee, S.
    Li, S.
    Snodgrass, P.
    Navarro, M.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S638 - S638
  • [29] Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
    Jones, Lauren
    Rittberg, Rebekah
    Leung, Bonnie
    Shokoohi, Aria
    Pender, Alexandra
    Wong, Selina
    Al-Hashami, Zamzam
    Wang, Ying
    Ho, Cheryl
    CURRENT ONCOLOGY, 2022, 29 (11) : 8686 - 8692
  • [30] Baseline Derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Clinical Outcomes to First-Line Pembrolizumab in NSCLC with High PD-L1 (≥50%)
    Alessi, J. V.
    Ricciuti, B.
    Alden, S.
    Awad, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S338 - S339
12345